Sara Małgorzata Orłowska

Ms. Sara Małgorzata Orłowska

Uniwersytet Radomski, Radom, Mazowieckie, Poland
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Małgorzata Katarzyna KowalskaMałgorzata Katarzyna Kowalska
Małgorzata Katarzyna Kowalska
AEAhmed El-Mallul El-Mallul
Ahmed El-Mallul El-Mallul
WHWeronika Anna Hudecka
Weronika Anna Hudecka
JMJoanna Elżbieta Majewska
Joanna Elżbieta Majewska
PLPiotr Jan Lubojański
Piotr Jan Lubojański
ŁBŁukasz Michal Bednarczyk
Łukasz Michal Bednarczyk
The aim of this article is to present the current state of knowledge regarding the use of GLP-1 agonists in the treatment of type 2 diabetes, obesity, and other potential clinical indications, including neurodegenerative conditions. The article describes the characteristics of the diseases discussed, with particular emphasis on the pathophysiological mechanisms and the impact of metabolic disorders on the course of the diseases. In addition, the specific role of GLP-1 receptor agonists and their mechanisms of action leading to improved clinical outcomes were discussed, including their impact on molecular pathways involved in glucose metabolism regulation, inflammatory processes, carcinogenesis, and neuroprotection. Based on meta-analyses of available clinical trials, the evidence supporting the effectiveness of GLP-1 agonist therapy in glycemic control, weight loss, and improvement of metabolic parameters was synthesized. Additionally, potential benefits beyond the metabolic system are discussed, including neuroprotective effects and impact on patients’ cardiovascular profiles, as well as risks and adverse effects associated with the use of GLP-1 agonists. The collected data indicate the growing role of GLP-1 agonists as an innovative and effective therapeutic strategy, while emphasizing the need for further research in the context of new clinical indications.

15 September 2024 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Małgorzata Katarzyna KowalskaMałgorzata Katarzyna Kowalska
Małgorzata Katarzyna Kowalska
SOSara Małgorzata Orłowska
Sara Małgorzata Orłowska
ŁBŁukasz Michal Bednarczyk
Łukasz Michal Bednarczyk
Atopic dermatitis is a chronic and multifactorial inflammatory dermatosis. Recurrent eczematous lesions and intense pruritus very often reduce the quality of life of patients, affecting their mental health. For this reason, it is necessary to undertake treatment. Treatment should be characterized by an individual approach to the patient, taking into account the predominant pathogenetic factors in the development of atopic dermatitis and systematic skin care. Soothing the typical symptoms of AD, i.e., dry skin and persistent itching, involves emollients, which counteract xerosis and reduce the feeling of itching. Studies confirm that the regular use of emollients in patients with AD prolongs the period between relapses and alleviates the intensity of symptoms during periods of disease severity. This review paper aims to highlight the challenges that patients with atopic dermatitis face. This work will also present an indication of the rationale for the use of emollients in this condition, as well as an indication of the forms of their application in therapeutic and care preparations.
1

Verified
Journal Article
Open access
PDF file
Małgorzata Katarzyna KowalskaMałgorzata Katarzyna Kowalska
Małgorzata Katarzyna Kowalska
AEAhmed El-Mallul El-Mallul
Ahmed El-Mallul El-Mallul
JMJoanna Elżbieta Majewska
Joanna Elżbieta Majewska
WHWeronika Anna Hudecka
Weronika Anna Hudecka
SOSara Małgorzata Orłowska
Sara Małgorzata Orłowska
ŁBŁukasz Michal Bednarczyk
Łukasz Michal Bednarczyk
This review covers issues related to the characteristics, diagnosis, and treatment of colorectal cancer (CRC). It discusses traditional methods of treating colorectal cancer, including surgery, chemotherapy, and radiotherapy, as well as modern approaches, including targeted therapies, immunotherapy, and innovative gene therapy strategies. Particular attention is paid to the identification of molecular subtypes of CRC, which has revolutionized treatment in advanced stages of the disease and contributed to improved patient survival. The role of biomarkers, including liquid biopsy, in diagnosis, therapy monitoring, and treatment response assessment is emphasized. The potential of artificial intelligence in planning and optimizing surgical procedures is also discussed, opening up new possibilities in personalized therapy. This article provides up-to-date knowledge on the molecular mechanisms of CRC, diagnostic prospects, and directions for the development of precision therapies, serving as a valuable source of information for both clinicians involved in the treatment of CRC and patients wishing to deepen their knowledge of the disease and modern therapeutic options.

17 June 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Małgorzata Katarzyna KowalskaMałgorzata Katarzyna Kowalska
Małgorzata Katarzyna Kowalska
SOSara Małgorzata Orłowska
Sara Małgorzata Orłowska
ŁBŁukasz Michal Bednarczyk
Łukasz Michal Bednarczyk
JMJoanna Elżbieta Majewska
Joanna Elżbieta Majewska
WHWeronika Anna Hudecka
Weronika Anna Hudecka
Psoriasis is a chronic inflammatory skin disease with a complex clinical picture that remains incurable and requires ongoing dermatological care. The purpose of this literature review is to identify the latest therapeutic strategies used to treat psoriasis, taking into account both the efficacy of modern approaches and their impact on patients’ quality of life. The cornerstone of psoriasis treatment remains regular skin care through the use of emollients, which support the effectiveness of other topical therapies used such as corticosteroids. In addition, the review presents current epidemiological data on the prevalence of psoriasis worldwide, with a focus on European countries and Poland. The article discusses innovative approaches in therapy, including targeted biologics, modern forms of topical therapy, and the role of emollients in comprehensive skin care, as well as various cosmetological treatments aimed at removing the excessively accumulated stratum corneum, and improving the degree of hydration of psoriatic skin. The review also included current expert recommendations and guidelines from scientific societies that guide the treatment and care of psoriatic skin. The results of the analyses underscore the need for targeted therapies and the importance of a holistic approach to patient care. As the collected data indicate, the possibilities for effective topical and systemic treatment of psoriasis are increasing all the time due to research into newer and newer active substances that are expected to improve the efficacy of treatment, the comfort of life for psoriasis patients and reduce the side effects of long-term therapy.

25 November 2025 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
MOMaria Ochwat
Maria Ochwat
OOOliwia Osiak
Oliwia Osiak
APAnna Piecha
Anna Piecha
JPJagoda Pawlak
Jagoda Pawlak
SOSara Małgorzata Orłowska
Sara Małgorzata Orłowska
MOMichał Oborski
Michał Oborski
Introduction and purposeThe diagnosis of OSA in children is based on clinical symptoms and polysomnography (Apnea-Hypopnea Index ≥1 or hypoventilation). The ICSD-3 (International Classification of Sleep Disorders - Third Edition) guidelines are also utilized. Diagnostics are supported by pulse oximetry, lateral nasopharyngeal X-ray, cephalometry, fiberoptic endoscopy, and magnetic resonance imaging of the upper respiratory tract. OSA is associated with serious complications, including behavioral disorders, cardiovascular complications, metabolic disorders, and growth disturbances. Children with OSA also experience learning difficulties and lower school performance. Treatment includes adenotonsillectomy, CPAP/BiPAP therapy, surgical procedures, weight reduction, and pharmacotherapy. The effectiveness of treatment may be limited, particularly in obese children. Post-treatment monitoring of patients is necessary due to the risk of residual symptoms. Material and methodsThe literature available in Pubmed and Google Scholar databases was conducted using the key words. ResultsData indicate that OSA occurs in approx. 5% of children, especially during the preschool years and adolescence. Symptoms include loud snoring, respiratory pauses, behavioral disorders, school difficulties, and daytime sleepiness. Polysomnography remains the cornerstone of diagnosis, supported by the PSQ and modified STOP-BANG questionnaires. Untreated OSA leads to metabolic, cardiovascular, and neurobehavioral complications. Treatment includes adenotonsillectomy, PAP therapy, weight reduction, pharmacotherapy, and orthodontic management. Conclusions Obstructive sleep apnea in children is a disorder with significant health consequences, requiring prompt diagnosis and tailored treatment. Adenotonsillectomy is the primary treatment method, with additional therapies applied to patients with persistent symptoms or contraindications to surgery.

Verified
Journal Article
Open access
PDF file
SOSara Małgorzata Orłowska
Sara Małgorzata Orłowska
ŁBŁukasz Michal Bednarczyk
Łukasz Michal Bednarczyk
KMKamal Morshed
Kamal Morshed
MTMateusz Tyniec
Mateusz Tyniec
POPawel Olczyk
Pawel Olczyk
Vogt–Koyanagi–Harada syndrome (VKH) is a rare granulomatous autoimmune disease characterised by a systemic immune response directed against melanocytes. This multisystem condition primarily affects organs that are rich in melanocytes, such as the eyes, inner ear, meninges and skin. VKH might be responsible for the development of chronic uveitis and permanent visual impairment, particularly in cases where a diagnosis is delayed and treatment is not administered in a timely manner. A key factor in its pathogenesis is the loss of immune tolerance to melanocytes, driven by a T-cell–mediated immune response and genetic susceptibility, including the presence of HLA-DRB1*04 antigens. In recent years, immune checkpoint inhibitors (ICIs) have become the standard treatment in oncology, including non-small cell lung cancer and unresectable melanoma. However, it should be noted that their utilisation carries with it the potential for immune-related adverse events, including rare cases of VKH-like uveitis. The objective of this review is to outline the clinical features of VKH syndrome, examine current diagnostic and treatment approaches, and emphasise the immunopathological mechanisms associated with drug-induced forms of VKH, with a particular focus on programmed cell death protein 1 (PD-1) inhibitors. The article also includes an analysis of the genetic, epigenetic, and environmental factors that predispose individuals to the disease. This analysis facilitates a deeper understanding of the pathogenesis of the disease and assists in the identification of patients at increased risk of drug-induced VKH manifestations.